The global ineffective esophageal motility treatment market is expected to grow at a CAGR of 6% and reach US$6.4 billion by 2030. With the way healthcare data is accumulated these days (which could include medical IoT solutions, DICOM files, and patient records), state-of-the-art platforms such as data fabrics are in sight, so that distributed and structured data can be well managed. This would be the situation of the healthcare industry in the coming period.
Ineffective treatment of esophageal motility results in reduced muscle damage and better outcomes, improving quality of life and leading to long-term benefits. Device-based treatment and IEMT medications have already had a substantial impact on how symptoms of GERD and achalasia are treated.
How about browsing the sample of Ineffective Esophageal Motility Treatment market report? https://www.persistencemarketresearch.com/samples/31550
The first and most important growth factor for the ineffective esophageal motility treatment market is the rising prevalence of gastroesophageal reflux disease. Other factors such as intake of asthma medications and increasing geriatric population are also responsible for the inefficiency of the esophageal motility treatment market.
According to the latest report published by PMR, the global ineffective esophageal motility treatment market is expected to grow at a decent CAGR of around 6% during the forecast period (2020-2030).
Companies Covered in Ineffective Esophageal Motility Treatment Market Report
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Bausch Health Companies Inc.
Mederi Therapeutics, Inc.
Becton, Dickinson and Company (CR Bard, Inc.)
EndoGastric Solutions, Inc.
What about step by step information about Ineffective Esophageal Motility Treatment Market? Look through the “methodology” employed! https://www.persistencemarketresearch.com/methodology/31550
Key Insights from Market Research on Ineffective Esophageal Motility Treatment
Significant benefits of ineffective treatment of esophageal motility; improvement of the reimbursement scenario for surgical treatment devices; increase awareness of gastric reflux disease; and the large pool of patients for GERD, dysphagia, achalasia, and burning chest pain are key factors propelling the growth of the ineffective esophageal motility treatment market in developing regions.
North America is a leading region in the global ineffective esophageal motility treatment market, while East Asia is expected to offer lucrative growth opportunities, due to the large population base and higher incidence of GERD and dysphagia.
Higher consumption of over-the-counter antacids is poised to drive the market growth.
Radiofrequency ablation systems with high-level precision and procedural advantages over myotomy are expected to generate significant revenue over the long term.
The increasing adoption of ineffective esophageal motility treatment drugs for rapid recovery compared to device-based treatment marks higher revenue potential.
Raw material supply issues, drug shortages and reduction in patient visits amid the COVID-19 pandemic will negatively affect the growth of the ineffective esophageal motility treatment market in the short term.
“Procedural precision achieved by treatment devices and affordability of drug treatments are expected to drive the ineffective esophageal motility treatment market. Moreover, the large pool of patients will bring stable revenue opportunities,” says a PMR analyst.
Want to keep an eye on the latest findings in the ineffective esophageal motility treatment market? Buy our Ineffective Esophageal Motility Treatment Market Report Now! https://www.persistencemarketresearch.com/checkout/31550
New product launches by key players to strengthen market presence
The major manufacturers of Ineffective Esophageal Motility Treatment market are majorly focused on research and development and introduction of new and advanced treatment products. For example, LINX is the new advanced version of LINX reflux management device which is used for transoral incisionless fundoplication process, which is one of the important procedures for the treatment of gastroesophageal reflux disease.
The innovation of new and advanced products is a driving factor for the ineffective esophageal motility treatment market. Also, Olympus Corporation introduced advanced versions of esophagoscopes, which improved the treatment curve for gastroesophageal reflux disease. Manufacturers are focusing on an expanded list of indications and higher reimbursement to attract demand and increase profitability.
Alternatively, a key factor affecting the ineffective esophageal motility treatment market is the entry of generic drug manufacturers. Market leaders are constantly working to strengthen their strategies to gain market share.
What else is in the report?
Persistence Market Research offers a unique perspective and actionable insights into the ineffective esophageal motility treatment market in its latest study, presenting a historical demand assessment from 2015-2019 and projections for 2020-2030, based on product (drugs and devices), indication (GERD, dysphagia, achalasia and burning chest pain) and end user (institutional and retail sales), across seven key regions.
Access related reports-
Medical Marijuana Market: https://www.persistencemarketresearch.com/market-research/medical-marijuana-market.asp
Precision medicine market: https://www.persistencemarketresearch.com/market-research/precision-medicine-market.asp
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York, NY 10007 USA
Telephone in the United States – +1-646-568-7751
USA-Canada Toll Free – +1 800-961-0353
Sales – [email protected]
Persistence Market Research (PMR), as a third-party research organization, operates through a proprietary fusion of market research and data analytics to help businesses soar high, regardless of the turbulence encountered due to the financial/natural crises.
This press release was published on openPR.